Encouraging Trends in Modern Phase 1 Oncology Trials
- 7 June 2018
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 378 (23) , 2242-2243
Abstract
Critics have raised a fundamental ethical challenge about phase 1 cancer research. They point to an expected paucity of benefits, since approximately 5% of patients in phase 1 trials are reported to have tumor shrinkage.1,2Keywords
This publication has 4 references indexed in Scilit:
- Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnosticAnnals of Oncology, 2017
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Response rates, duration of response, and dose response effects in phase I studies of antineoplasticsInvestigational New Drugs, 1991
- Responses and toxic deaths in Phase I clinical trialsAnnals of Oncology, 1990